Emergency Medicine Cases – Where the Experts Keep You in the Know. For show notes, quizzes, videos and more learning tools please visit emergencymedicinecases.com
…
continue reading
Sisällön tarjoaa PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
Linda R. Duska, MD, MPH / Debra L. Richardson, MD, FACS, FACOG - Upgrading the Treatment Algorithm for Advanced Ovarian Cancer: Expert Tips, Tools, and Patient Care Strategies for Making the Most of PARP Inhibitors Across the Disease Continuum
M4V•Jakson koti
Manage episode 364922402 series 103655
Sisällön tarjoaa PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Go online to PeerView.com/UNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this discussion-based activity, two experts on ovarian cancer discuss the role of PARP inhibitors in treating advanced ovarian cancer. Upon completion of this activity, participants should be better able to: Adapt workflows to ensure that patients with ovarian cancer are receiving timely and appropriate genetic testing for BRCA, HRD, and other mutations that can help determine the role of PARP inhibitor therapy; Cite current efficacy and safety evidence on PARP inhibitors in different populations of patients with ovarian cancer; Utilize PARP inhibitors in the appropriate management of patients with ovarian cancer, including within the context of clinical trials, in accordance with current clinical evidence, guideline recommendations, mutation status, and patient needs and preferences; and Employ collaborative strategies to recognize and manage adverse events related to PARP inhibitor use in patients with ovarian cancer
…
continue reading
57 jaksoa
Linda R. Duska, MD, MPH / Debra L. Richardson, MD, FACS, FACOG - Upgrading the Treatment Algorithm for Advanced Ovarian Cancer: Expert Tips, Tools, and Patient Care Strategies for Making the Most of PARP Inhibitors Across the Disease Continuum
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
M4V•Jakson koti
Manage episode 364922402 series 103655
Sisällön tarjoaa PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Go online to PeerView.com/UNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this discussion-based activity, two experts on ovarian cancer discuss the role of PARP inhibitors in treating advanced ovarian cancer. Upon completion of this activity, participants should be better able to: Adapt workflows to ensure that patients with ovarian cancer are receiving timely and appropriate genetic testing for BRCA, HRD, and other mutations that can help determine the role of PARP inhibitor therapy; Cite current efficacy and safety evidence on PARP inhibitors in different populations of patients with ovarian cancer; Utilize PARP inhibitors in the appropriate management of patients with ovarian cancer, including within the context of clinical trials, in accordance with current clinical evidence, guideline recommendations, mutation status, and patient needs and preferences; and Employ collaborative strategies to recognize and manage adverse events related to PARP inhibitor use in patients with ovarian cancer
…
continue reading
57 jaksoa
Kaikki jaksot
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.